CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Follicular NHL, grades 1 or 2 confirmed by biopsy
  • ✓Age 18 years or older
  • ✓Evidence of disease progression at study entry
  • ✓Prior chemotherapy: 1-2 regimens required
Key exclusion· 5
  • ✕Prior bevacizumab or similar agents
  • ✕Progressive disease <6 months after rituximab
  • ✕CNS involvement with NHL
  • ✕>1 prior treatment with investigational agents within 4 weeks

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00193492
NCT00193492Phase 2Completed
CompareCT.gov

Rituximab +/- Bevacizumab in the Treatment of Patients With Follicular Non-Hodgkin's Lymphoma: A Randomized, Phase II Trial

SCRI Development Innovations, LLC·interventional·Posted Sep 19, 2005·Updated Jan 5, 2015

In Brief

A Phase 2 clinical trial evaluating Bevacizumab and Rituximab for Lymphoma, Follicular. Completed, enrolled 60 participants across 22 sites.

Detailed Summary

The purpose of this study is to assess the feasibility, efficacy and safety of adding bevacizumab to rituximab compared to rituximab alone in patients with previously treated follicular non-hodgkin's lymphoma (NHL) whose disease has progressed following at least one previous chemotherapy regimen and not more than 2 previous chemotherapy regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Follicular
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 19, 2005
Enrollment StartSep 1, 2005
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 20.8 years ago

Interventions

Bevacizumabdrug

Rituximabdrug